|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-1-21
|
|
pubmed:abstractText |
To investigate a 1-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for rescue therapy of Helicobacter pylori infection.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Aryl Hydrocarbon Hydroxylases,
http://linkedlifedata.com/resource/pubmed/chemical/Aza Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/CYP2C19 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Clarithromycin,
http://linkedlifedata.com/resource/pubmed/chemical/Metronidazole,
http://linkedlifedata.com/resource/pubmed/chemical/Mixed Function Oxygenases,
http://linkedlifedata.com/resource/pubmed/chemical/Omeprazole,
http://linkedlifedata.com/resource/pubmed/chemical/Quinolines,
http://linkedlifedata.com/resource/pubmed/chemical/Rifabutin,
http://linkedlifedata.com/resource/pubmed/chemical/moxifloxacin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1523-5378
|
|
pubmed:author |
pubmed-author:BästleinElkeE,
pubmed-author:HaferlandChristianC,
pubmed-author:JebensClausC,
pubmed-author:KirschChristianC,
pubmed-author:KnothHolgerH,
pubmed-author:KuhlischEberhardE,
pubmed-author:LehnNorbertN,
pubmed-author:MadischAhmedA,
pubmed-author:MiehlkeStephanS,
pubmed-author:MorgnerAndreaA,
pubmed-author:Schneider-BrachertWulfW,
pubmed-author:StolteManfredM,
pubmed-author:ZekornChristianC
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
69-74
|
|
pubmed:meshHeading |
pubmed-meshheading:18205669-Adult,
pubmed-meshheading:18205669-Aged,
pubmed-meshheading:18205669-Anti-Bacterial Agents,
pubmed-meshheading:18205669-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:18205669-Aza Compounds,
pubmed-meshheading:18205669-Clarithromycin,
pubmed-meshheading:18205669-Drug Resistance, Bacterial,
pubmed-meshheading:18205669-Drug Therapy, Combination,
pubmed-meshheading:18205669-Female,
pubmed-meshheading:18205669-Gastric Mucosa,
pubmed-meshheading:18205669-Helicobacter Infections,
pubmed-meshheading:18205669-Helicobacter pylori,
pubmed-meshheading:18205669-Humans,
pubmed-meshheading:18205669-Male,
pubmed-meshheading:18205669-Metronidazole,
pubmed-meshheading:18205669-Middle Aged,
pubmed-meshheading:18205669-Mixed Function Oxygenases,
pubmed-meshheading:18205669-Omeprazole,
pubmed-meshheading:18205669-Polymorphism, Restriction Fragment Length,
pubmed-meshheading:18205669-Prospective Studies,
pubmed-meshheading:18205669-Quinolines,
pubmed-meshheading:18205669-Rifabutin
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin.
|
|
pubmed:affiliation |
Medical Department I, Technical University Hospital, Dresden, Germany. stephan.miehlke@uniklinikum-dresden.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
